Skip to content

DMT: all studies

Page 111 of 160: studies 1,101 to 1,110 of 1,593, newest first. Back to the DMT overview

Research

Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research

Addiction Neuroscience June 22, 2022 Fúlvio Rieli Mendes, Cristiane Dos Santos Costa, Victor Distefano Wiltenburg et al. 55 citations

Substance use disorder (SUD) is a global public health concern that affects millions of people worldwide. Considering current research, addiction has been noted as the last stage of a chronic disease that may impair brain reward circuit responses and affects personal and social life. Treatments for SUD face challenges including availability and limited pharmacological response, often resulting...

Sustained effects of single doses of classical psychedelics in humans.

Neuropsychopharmacology June 21, 2022 Gitte M. Knudsen 56 citations

The serotonergic classical psychedelics include compounds that primarily activate the brain's serotonin 2 A receptor (5-HT2AR), such as LSD, psilocybin, and DMT (ayahuasca). The acute effects of these compounds are well-known as are their ability to increase the emotional state both in healthy people and in those with neuropsychiatric disorders. In particular psilocybin, the psychoactive...

DOI: 10.1038/s41386-022-01361-x (opens in new tab) Full text (opens in new tab) Psychedelics Mental health Therapeutic treatment Depression treatment +1

β-carboline-independent antidepressant-like effect of the standardized extract of the barks of Mimosa tenuiflora (Willd) Poir. occurs via 5-HT2A/2C receptors in mice

Journal of Psychopharmacology June 20, 2022 Luiz Antonio Miranda de Souza Duarte Filho, Isabela Araújo E Amariz, Rodolfo Hideki Vicente Nishimura et al. 12 citations

Background: Depression is a psychiatric disorder with limited therapy options. Psychedelics are new antidepressant candidates, being the ayahuasca one of the most promising ones. A synergistic combination of N,N-dimethyltryptamine (DMT) and β-carbolines allows ayahuasca antidepressant properties. Another psychedelic and DMT-containing beverage is the jurema wine used religiously by indigenous...

DOI: 10.1177/02698811221104050 (opens in new tab) Antidepressant Traditional medicine Pharmacology Receptor

The promises and perils of psychedelic pharmacology for psychiatry.

Nature Reviews Drug Discovery June 1, 2022 Tristan D Mcclure-Begley, Bryan L. Roth 195 citations

Psychedelic drugs including psilocybin, N,N'-dimethyltryptamine (DMT) and lysergic acid diethylamide (LSD) are undergoing a renaissance as potentially useful drugs for various neuropsychiatric diseases, with a rapid onset of therapeutic activity. Notably, phase II trials have shown that psilocybin can produce statistically significant clinical effects following one or two administrations in...

Possible Therapeutics Effects of Ayahuasca, a Psychedelic Compound

European Psychiatry June 1, 2022 L. Silva, L. Bravo

Introduction Ayahuasca is an hallucinogenic tea prepared from the Amazonian vine Banisteriopsis caapi and the leaves of the plant Psychotria Viridis. Banisteriopsis caapi contains monoamine oxidase inhibitors (MAO) that render the N, N-dimethyltryptamine (DMT) of Psychotria Viridis active. This brew is being used as a sacrament in syncretic religions in urban areas of Brazil and worldwide with...

Sipping the virtual elixir: An autoethnographic close reading of Ayahuasca Kosmik Journey, a self-transcendent virtual experience

Virtual Creativity June 1, 2022 Noah Miller, John Desnoyers-Stewart, Ekaterina R. Stepanova et al. 2 citations

Self-transcendent experiences are often an integral component of ancient cultural practices that use psychedelic substances during spiritual ceremonies, such as ayahuasca ceremonies. Yet, ayahuasca contains dimethyltryptamine (DMT), which is illegal in many countries. Due to its illegality, ayahuasca experiences are scarce despite potential benefits of increased quality of life and reduced...

DOI: 10.1386/vcr_00059_1 (opens in new tab) Ayahuasca Autoethnography Narrative Aesthetics +7

A Review of Aeruginascin and Potential Entourage Effect in Hallucinogenic Mushrooms

European Psychiatry June 1, 2022 Pierre Chue, A. Andreiev, E. Bucuci et al. 6 citations

Introduction The 5-HT 2A agonist classic psychedelic, psilocybin (O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine) is a tryptophan, indole-based alkaloid present in up to 2% of certain hallucinogenic “magic” mushroom species; typically Psilocybe azurescens, semilanceata, and cyanescens,. In addition, mushrooms may contain psilocin (4-hydroxy-N,N-dimethyltryptamine). Both are indolylalkylamines...

The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides.

Psychopharmacology June 1, 2022 Pablo Mallaroni, Natasha L. Mason, F R J Vinckenbosch et al. 16 citations

Novel psychedelics (NPs) are an expanding set of compounds, presenting new challenges for drug policy and opportunities for clinical research. Unlike their classical derivatives, little is known regarding their use profiles or their subjective effects. The purpose of this study was to compile usage patterns and adverse event rates for individual NPs belonging to each of three main psychedelic...

DOI: 10.1007/s00213-022-06142-4 (opens in new tab) Full text (opens in new tab) 2–4-bromo-2,5-dimethoxyphenylethanamine 2c-b 4-Acetoxy-N,N-Dimethyltryptamine 4-Aco-DMT Hallucinogen Lysergamide +4

THE BENEFITS OF PSYCHEDELIC THERAPY FOR MENTAL HEALTH: EXPLORING PSYCHEDELICS

Zenodo (CERN European Organization for Nuclear Research) May 13, 2022 Liliana Irizabal preprint

This project is a systematic review that highlights how beneficial psychedelic psychotherapy can be to those suffering with mental illness. The three mental illnesses chosen to be analyzed in the literature were depression, post-traumatic stress disorder (PTSD), and anxiety. The drugs used in the specific articles included Psilocybin, Ayahuasca(DMT), and MDMA (3,4-methylenedioxymethamphetamine;...

DOI: 10.5281/zenodo.6654351 (opens in new tab) Psilocybin Mental health Psychotherapist Clinical psychology +1

Sober sitter or coconsumer? Psychedelics, online forums and preferences for interpersonal interactions

Addiction Research & Theory May 6, 2022 Sascha Thal, Liam Engel, Stephen Bright

Abstract Contemporary clinical research into the psychotherapeutic administration of psychedelics has primarily emphasized the importance of therapeutic interpersonal interactions to assist clients prepare for and integrate the acute effects of psychedelics. Alternative therapeutic frameworks have encouraged active talk therapy between therapists and clients during the administration phase. We...